Novan (NOVNW) FCF Yield % : -178,486.36 (As of Dec. 15, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novan FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Novan's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, Novan's FCF Yield % for today is -178,486.36%.

The historical rank and industry rank for Novan's FCF Yield % or its related term are showing as below:

NOVNW' s FCF Yield % Range Over the Past 10 Years
Min: -1503561.04 Med: -57.73 Max: -8.67
Current: -178486.36

During the past 9 years, the highest FCF Yield % of Novan was -8.67%. The lowest was -1503561.04%. And the median was -57.73%.

NOVNW's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -12.96 vs NOVNW: -178486.36

Novan's FCF Margin % for the quarter that ended in Mar. 2023 was -142.62%.

Novan FCF Yield % Historical Data

The historical data trend for Novan's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novan FCF Yield % Chart

Novan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Yield %

Get a 7-Day Free Trial

Novan Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
FCF Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Novan's FCF Yield %

For the Biotechnology subindustry, Novan's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novan's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novan's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Novan's FCF Yield % falls into.

Novan FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Novan's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-35.156	/
	=	N/A%

Novan's annualized FCF Yield % for the quarter that ended in Mar. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-4.273	*	4	/
	=	N/A%

Novan FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Novan FCF Yield % Related Terms

Thank you for viewing the detailed overview of Novan's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novan Inc (OTCPK:NOVNW) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.